Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Eton Pharmaceuticals, Inc. ETON
$55.36 +6.50% Close, Oct 2, 2026 · NASDAQ · Market cap $1.52B
Strong growthStrong trend
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $105.6M, up 81.5% from a year earlier.
- Operating margin widened to 15.4% from -1.4% a year earlier.
- The diluted share count rose 21.9% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth89Strong
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 12%
- FCF growth (TTM, YoY)Top 44%
- Revenue growth, 3-year CAGRTop 12%
- Revenue growth accelerationTop 31%
Quality78Positive
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 5%
- Gross marginBottom 43%
- Operating marginTop 18%
- Cash conversion (OCF / net income)Bottom 31%
- Accruals (lower is better)Bottom 25%
- Net debt / EBITDA (lower is better)Top 39%
- Interest coverTop 23%
Value62Neutral
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 28%
- Free-cash-flow yieldTop 33%
- EBITDA / enterprise valueTop 34%
- Sales / enterprise valueBottom 25%
Momentum96Exceptional
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 7%
- 6-month returnTop 6%
- 1-year return vs S&P 500Top 6%
- Distance from 52-week highTop 25%
- Trend checklist (0–4)Top 20%
Revisions35Weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 15%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 27%
Stability67Positive
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 9%
- Maximum drawdown, 3 yearsTop 12%
- Beta vs S&P 500 (lower is better)Top 19%
- Net debt / EBITDA (lower is better)Top 39%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 79.9% | 81.5% | ↑ |
| Gross margin | 59.4% | 57.9% | ↓ |
| Operating margin | -1.4% | 15.4% | ↑ |
| FCF margin | 21.0% | 14.0% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 81.5% | 79.9% | ↑ | Top 12% |
| Gross margin | 57.9% | 59.4% | ↓ | Bottom 43% |
| Operating margin | 15.4% | -1.4% | ↑ | Top 18% |
| Net margin | 12.0% | -7.1% | ↑ | — |
| Free-cash-flow margin | 14.0% | 21.0% | ↓ | — |
| Return on invested capital | 20.4% | — | Top 5% | |
| Revenue growth, 3-year CAGR | 55.5% | — | Top 12% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.19×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -2.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 4.9%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -9.3 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 0.12×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 6.1×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.31%
- Shareholder yield
- -0.31%
- Share count change, 1 year
- +21.9%
- Share count change, 3-year CAGR
- +8.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -41.9%
- Average 2-day reaction, last 8
- -0.9%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $66.67
- Target vs current price
- +20.4%
- Analysts with a rating
- 7
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | +84.4% | -1.9% | +47.9% | +39.2% | — |
| May 14, 2026 | -50.0% | -2.8% | +11.8% | +4.2% | +41.7% |
| Mar 19, 2026 | -58.3% | +9.2% | +25.3% | +28.4% | +66.1% |
| Nov 6, 2025 | -143.8% | -0.6% | -9.3% | -12.7% | -20.1% |
| Aug 7, 2025 | -900.0% | +0.0% | +12.2% | +17.1% | +19.6% |
| May 13, 2025 | -22.2% | -1.6% | +12.8% | -9.5% | -12.0% |
| Mar 18, 2025 | +0.0% | -4.0% | -3.3% | -10.3% | -1.3% |
| Nov 12, 2024 | +400.0% | -5.6% | +3.3% | +24.0% | +76.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | $0.35 | $0.19 | +84.4% | $37.6M |
| May 14, 2026 | $0.05 | $0.10 | -50.0% | $24.3M |
| Mar 19, 2026 | $0.05 | $0.12 | -58.3% | $21.3M |
| Nov 6, 2025 | -$0.07 | $0.16 | -143.8% | $22.5M |
| Aug 7, 2025 | -$0.10 | -$0.01 | -900.0% | $18.9M |
| May 13, 2025 | $0.07 | $0.09 | -22.2% | $17.3M |
| Mar 18, 2025 | -$0.02 | -$0.02 | +0.0% | $11.6M |
| Nov 12, 2024 | $0.02 | $0.00 | +400.0% | $10.3M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 143.9× | — | — | Top 28% |
| P/E (forward) | 50.9× | — | — | — |
| EV / EBITDA | 81.8× | — | — | Top 34% |
| EV / Sales | 14.38× | — | — | Bottom 25% |
| Free-cash-flow yield | 0.97% | — | — | Top 33% |
| Earnings yield | 0.69% | — | — | Top 28% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 1
- Days above the 200-day average
- 144
- 50-day average slope (20 days)
- +15.5%
- 200-day average slope (20 days)
- +14.4%
- Distance from 50-day average
- +1.4%
- Distance from 200-day average
- +72.4%
- RSI (14)
- 48.6
- Relative volume
- 1.30×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 97.8%
- Volatility vs own 5-year history
- 95th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.57
- Correlation with S&P 500
- 0.14
- Current drawdown from 1-year high
- -14.1%
- Maximum drawdown, 3 years
- -39.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 17, 2021 | Oct 20, 2022 | -79.9% | 423 days | 519 days (Nov 13, 2024) |
| Feb 5, 2025 | Apr 8, 2025 | -37.1% | 43 days | 26 days (May 15, 2025) |
| Sep 29, 2025 | Feb 5, 2026 | -36.2% | 89 days | 31 days (Mar 23, 2026) |
| May 22, 2025 | Jun 25, 2025 | -33.3% | 22 days | 65 days (Sep 26, 2025) |
| May 21, 2026 | Jun 2, 2026 | -21.7% | 7 days | 17 days (Jun 26, 2026) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.52B
- P/E (TTM)
- 143.9
- EPS, diluted (TTM)
- $0.38
- Revenue (TTM)
- $105.6M
- 52-week range
- $14.27 – $66.37
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $21.8M | $21.3M | $31.6M | $39.0M | $80.0M |
| Gross profit | $19.2M | $14.3M | $21.1M | $23.4M | $42.7M |
| Operating income | -$1.5M | -$8.3M | -$1.2M | -$2.6M | $72,000 |
| Net income | -$2.0M | -$9.0M | -$936,000 | -$3.8M | -$4.6M |
| EPS (diluted) | -$0.08 | -$0.36 | -$0.04 | -$0.15 | -$0.17 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3M | $11.6M | $17.3M | $18.9M | $22.5M | $21.3M | $24.3M | $37.6M |
| Net income | $627,000 | -$598,000 | -$1.6M | -$2.6M | -$1.9M | $1.5M | $1.6M | $11.6M |
| EPS (diluted) | $0.02 | -$0.02 | -$0.06 | -$0.10 | -$0.07 | $0.05 | $0.05 | $0.35 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$4.7M | $4.8M | $6.8M | $969,000 | $10.5M |
| Capital expenditure | -$3.3M | -$2.8M | -$775,000 | -$26,000 | -$333,000 |
| Free cash flow | -$8.0M | $2.0M | $6.0M | $943,000 | $10.2M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $541,000 | $0 | $0 | $8.2M | $598,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $26.8M
- Total assets
- $115.8M
- Total liabilities
- $69.2M
- Total debt
- $29.0M
- Net debt
- $2.1M
- Shareholders’ equity
- $46.6M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 1,542,982
- Days to cover
- 3.52
- Change vs previous report
- +14.5%
FINRA short interest, settlement date Sep 15, 2026.